FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - January 7, 2026 292 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR When Caregiving Takes a Toll May 28, 2021 Worries About Medical Bills May Worsen Health Outcomes After Cancer Diagnosis March 13, 2021 EMA Recommends Granting a Conditional Marketing Authorisation for Nadofaragene Firadenovec April 24, 2026 Today is Veterans Day November 11, 2020 Load more HOT NEWS News digest – skin cancer deaths, Public Health England plans and... Trastuzumab Deruxtecan Shows Promising Activity Among Patients with HER2-positive and Signal... Smoking Initiation Shifting from Teens to Young Adults PSMA PET-CT Accurately Detects Prostate Cancer Spread, Trial Shows
